Regeneron Pharmaceuticals, Inc. (REGN) · Sep 30, 2026 · Other events

Regeneron grants CSO 2.9M-share PSU award through 2035, tying pay to pipeline output

2.9M-share PSU grant — Up to 2,900,000 shares; performance period runs through 2035

Regeneron’s new executive compensation award offers up to 2.9 million shares, linking long-term pay to drug filings, approvals, revenue, and succession.

Regeneron is a science-driven biotech with a broad pipeline spanning oncology, immunology, genetic medicines, and other therapeutic areas; it is trying to turn that research engine into a steady stream of new approvals and commercial products. Its pipeline includes nearly 50 clinical programs and several late-stage regulatory milestones.

This is a retention and incentive package, not a pipeline update. The company granted its Chief Scientific Officer a one-time award covering up to 2.9 million shares, with no additional equity awards permitted through December 31, 2035. 〔0〕 (Grant and Years 1-10)

Award componentFiling terms
Grant dateSeptember 24, 2026 (Grant Date)
Maximum award2,900,000 shares (Grant and Years 1-10)
Performance period2026–2035 (Years 1-10)
New-entity filing award10,000 PSUs per qualifying FDA BLA or NDA filing (New Entity Filing)
Approval award15,000 PSUs per qualifying new-product approval; 12,500 per eligible supplemental approval (Eligible Supplemental Filing)
Revenue award0 shares below $10 billion; 250,000 at $10 billion; 900,000 at $18 billion; 1,800,000 at $30 billion (Revenue Shares)
Relative TSR modifierDown 20% or up 20% versus the Nasdaq Biotechnology Index, subject to the plan’s limits (rTSR Measurement Period)

The design strongly rewards sustained scientific output and commercialization. The award pays for FDA filings, FDA approvals, and new-product revenue rather than simply continued employment, with revenue hurdles beginning at $10 billion and extending to $30 billion. (New Entity Filing; Eligible Supplemental Filing; Revenue Shares)

The package also locks in leadership continuity. While the recipient remains Chief Scientific Officer, Regeneron will nominate them to the board, and the recipient must participate in developing a CSO succession plan by the fifth anniversary of the grant. (Years 1-10)

The trade-off is unusually concentrated and long-dated compensation. The award aligns the company’s senior scientific leadership with pipeline productivity and future product revenue, but it also gives one executive a very large, front-loaded package and embeds board and succession arrangements through 2035. There is no clean external consensus benchmark for this type of award, so the right read is not beat or miss: it is a material retention mechanism with both incentive value and governance complexity.

Bottom line: Regeneron is converting its long-term drug-development ambitions into a highly concentrated, decade-long CSO incentive plan. It matters mainly for leadership retention and governance, not because it changes the pipeline today—annual certification of the first performance year is the next tangible checkpoint. (Years 1-10)

What to watch next

Annual certification of 2026 filings and approvals, January 2027

Original filing on SEC EDGAR

More Regeneron Pharmaceuticals, Inc. news

Regeneron grants CSO 2.9M-share PSU award through 2035, tying pay to pipeline output | REGN Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.